Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants.

McManus M, Mick E, Hudson R, Mofenson LM, Sullivan JL, Somasundaran M, Luzuriaga K; PACTG 356 Investigators..

PLoS One. 2016 Apr 22;11(4):e0154391. doi: 10.1371/journal.pone.0154391.

2.

HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment.

Luzuriaga K, Tabak B, Garber M, Chen YH, Ziemniak C, McManus MM, Murray D, Strain MC, Richman DD, Chun TW, Cunningham CK, Persaud D.

J Infect Dis. 2014 Nov 15;210(10):1529-38. doi: 10.1093/infdis/jiu297.

3.

Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.

Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP.

Virology. 2013 Nov;446(1-2):268-75. doi: 10.1016/j.virol.2013.08.002.

4.

Exploiting drug-resistant enzymes as tools to identify thienopyrimidinone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H.

Masaoka T, Chung S, Caboni P, Rausch JW, Wilson JA, Taskent-Sezgin H, Beutler JA, Tocco G, Le Grice SF.

J Med Chem. 2013 Jul 11;56(13):5436-45. doi: 10.1021/jm400405z.

5.

Effect of antiretroviral therapy on clinical and immunologic disease progression in HIV positive children: One-year follow-up study.

Patel A, Trivedi SS, Chudasama RK, Patel PK.

J Family Community Med. 2012 Sep;19(3):178-83. doi: 10.4103/2230-8229.102318.

6.

Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.

Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV.

Antimicrob Agents Chemother. 2012 Oct;56(10):5374-80. doi: 10.1128/AAC.00842-12.

7.

Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens.

Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord..

AIDS. 2011 Nov 28;25(18):2279-87. doi: 10.1097/QAD.0b013e32834d614c.

8.

Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.

Peacock-Villada E, Richardson BA, John-Stewart GC.

Pediatrics. 2011 Feb;127(2):e423-41. doi: 10.1542/peds.2009-2701. Review.

9.
10.

Pharmacotherapy of pediatric and adolescent HIV infection.

Schuval SJ.

Ther Clin Risk Manag. 2009 Jun;5(3):469-84.

11.

Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR.

Mehta N, Trzmielina S, Nonyane BA, Eliot MN, Lin R, Foulkes AS, McNeal K, Ammann A, Eulalievyolo V, Sullivan JL, Luzuriaga K, Somasundaran M.

PLoS One. 2009 Jun 5;4(6):e5819. doi: 10.1371/journal.pone.0005819.

12.

Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.

Sahu GK, Paar D, Frost SD, Smith MM, Weaver S, Cloyd MW.

J Med Virol. 2009 Jan;81(1):9-15. doi: 10.1002/jmv.21366.

13.

Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children.

Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA, Richardson BA, Overbaugh J, Emery S, Wariua G, Gichuhi C, Bosire R, John-Stewart G.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):311-7.

14.

A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.

Van Herrewege Y, Vanham G, Michiels J, Fransen K, Kestens L, Andries K, Janssen P, Lewi P.

Antimicrob Agents Chemother. 2004 Oct;48(10):3684-9.

15.

Nevirapine: an option for preventing as well as treating paediatric HIV infection.

[No authors listed]

Afr Health Sci. 2001 Aug;1(1):32-5. No abstract available.

16.

Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children.

Feeney ME, Roosevelt KA, Tang Y, Pfafferott KJ, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ.

J Virol. 2003 Jul;77(13):7492-501.

17.

Frequencies of ex vivo-activated human immunodeficiency virus type 1-specific gamma-interferon-producing CD8+ T cells in infected children correlate positively with plasma viral load.

Buseyne F, Scott-Algara D, Porrot F, Corre B, Bellal N, Burgard M, Rouzioux C, Blanche S, Rivière Y.

J Virol. 2002 Dec;76(24):12414-22.

18.

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.

Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R, Gange S, Quinn TC, Siliciano RF, Persaud D.

J Virol. 2002 Sep;76(18):9481-92.

19.

Impact of antiretroviral protocols on dynamics of AIDS progression markers.

Resino S, Bellón JM, Sánchez-Ramón S, Gurbindo D, Ruiz-Contreras J, León JA, Ramos JT, Muñóz-Fernández MA.

Arch Dis Child. 2002 Feb;86(2):119-24.

20.
Items per page

Supplemental Content

Support Center